Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 1_Pingwei Powder alleviates high-fat diet-induced colonic inflammation by modulating microbial metabolites SCFAs.xlsx by Tangjuan Liu (2634649)

“…Experimental validation showed that PWP significantly downregulated the levels of PI3K, pAKT/AKT, and pmTOR/mTOR in colonic tissue, thereby enhancing autophagy in colonic epithelial cells, as evidenced by decreased levels of P62 and increased LC3B-II/LC3B-I ratios. …”

Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Evolutionary tree analysis of ZmSTOMAGEN. by Juan-Juan Xu (18590868)

“…Compared to the wild-type plants (HiII-A × HiII-B), the <i>zmstomagen1/2</i> mutant exhibited significant alterations in phytohormone homeostasis. …”

Raw data for all figures. by Juan-Juan Xu (18590868)

“…Compared to the wild-type plants (HiII-A × HiII-B), the <i>zmstomagen1/2</i> mutant exhibited significant alterations in phytohormone homeostasis. …”

Data Sheet 2_The Emotional Recession: global declines in emotional intelligence and its impact on organizational retention, burnout, and workforce resilience.pdf by Joshua M. Freedman (22604039)

“…</p>Results<p>Global EQ scores declined by 5.79% (Cohen’s d = 0.22, 95% CI [0.17, 0.27]), with statistically significant decreases across all eight competencies (p < 0.001). …”

Data Sheet 4_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Overview of BDHS data. by Keith Beam (20700854)

“…<div><p>Oral zinc is a proven effective treatment for diarrheal illness, and long-term monitoring is key to evaluating the success of efforts to scale up zinc treatment. …”

Data Sheet 1_Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database.docx by Peiyang Cao (10808613)

“…</p>Conclusion<p>While tolvaptan provides therapeutic benefits, it poses a risk of significant adverse reactions. Clinicians should closely monitor the occurrence of events related to hepatobiliary disorders, renal and urinary disorders, metabolic and nutritional disorders, as well as benign, malignant, and indeterminate tumors during its clinical use.…”

Table 3_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.doc by Meizhi Liu (21898892)

“…</p>Results<p>In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually. …”

Data Sheet 2_Burden of NASH related liver cancer from 1990 to 2021 at the global, regional, and national levels.pdf by Shuang Li (146392)

“…At the national level, ASRs consistently decreased with higher SDI.</p>Conclusion<p>This study highlights the substantial burden of NRLC at global, regional, and national levels. …”